Pharmacy and pharmaceutical regulation in California: who writes the rules.
Agency decisions shape how policy works in practice. Explore the institutions and policy matters relevant to pharmaceutical organizations, then discuss the proceedings affecting your business.
Who writes and enforces the rules.
- California State Board of PharmacyLicensing, pharmacist-in-charge rules, remote and central-fill regulation, non-resident pharmacy oversight.
- Department of Health Care Access and Information (HCAI)Manufacturer cost and price transparency reporting; PBM data intake.
- Department of Managed Health Care (DMHC)PBM licensing, formulary and utilization review oversight, AI in utilization review.
- Department of Health Care Services (DHCS)CalRx, Medi-Cal Rx, and the Medi-Cal pharmacy benefit.
- California Department of Insurance (CDI)Insurer-side drug benefit oversight parallel to DMHC.
Rulemakings, programs, and enforcement in 2026.
- CalRxProgramState-brand biosimilar insulin. CalRx insulin glargine on sale in California since January 2026 at a suggested $55 per five-pack through the Civica partnership. In-state manufacturing funding was cut from the 2025–26 budget; expansion to other drug classes is a budget-cycle question. Live program.
- HCAI transparencyRulemakingManufacturer prescription drug cost and price reporting. Reporting cycle and penalty appeals under the state's drug price transparency program. Ongoing reporting cycle.
- Board of Pharmacy feesRulemakingFee-schedule rulemaking. Follows an audit finding the Board is not recovering its operating costs. Open rulemaking, 2026.
- Board of Pharmacy central fillRulemakingRemote order processing and central-fill pharmacies. Proposed regulatory framework, including amendments to central-fill location requirements. Open rulemaking, 2026.
Discuss your California
policy priorities.
Tell us what is changing for your organization.
We’ll discuss the representation and scope you need.